Resecabtagene autoleucel - Cabaletta Bio
Alternative Names: CABA-201; rese-celLatest Information Update: 05 Nov 2025
At a glance
- Originator Cabaletta Bio
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Yes - Myositis; Systemic scleroderma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Myasthenia gravis; Myositis; Systemic lupus erythematosus; Systemic scleroderma
- Phase I Pemphigus vulgaris
- Preclinical Multiple sclerosis
Most Recent Events
- 27 Oct 2025 Updated adverse events data from a phase I/II trial in Systemic lupus erythematosus released by Cabaletta Bio
- 27 Oct 2025 Updated efficacy and adverse events data from a phase I/II trial in Myositis released by Cabaletta Bio
- 27 Oct 2025 Updated efficacy and adverse events data from a phase I/II trial in Systemic sclerosis released by Cabaletta Bio